admin

admin

Roche and Hansoh Expand ADC Alliance

Hansoh Pharma and Roche entered a second antibody drug conjugate collaboration covering two undisclosed Hansoh preclinical programs and multiple Roche-proposed targets using Hansoh’s proprietary ADC platform. Hansoh will receive $400 million upfront and $110…

Bitopertin Phase 3 Meets Dual EPP Endpoints

Disc Medicine reported that the randomized Phase 3 APOLLO trial met both co-primary endpoints and every prespecified secondary endpoint in erythropoietic protoporphyria and X-linked protoporphyria. The result directly addresses the clinical-benefit evidence gap identified…